Open AccessTreatment of Opioid Use Disorder in Pregnant Women via Telemedicine
Author(s) -
Constance Guille,
Annie N. Simpson,
Edie Douglas,
Lisa Boyars,
Kathryn Cristaldi,
James T. McElligott,
Donna Johnson,
Kathleen T. Brady
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2019.20177
Subject(s) - medicine , opioid use disorder , buprenorphine , pregnancy , telemedicine , abstinence , psychological intervention , methadone , logistic regression , confounding , obstetrics , postpartum period , emergency medicine , pediatrics , health care , psychiatry , opioid , economics , genetics , economic growth , receptor , biology
Key Points Question Is opioid use disorder treatment received via telemedicine in obstetric practices associated with similar maternal and newborn outcomes compared with opioid use disorder treatment received in person in obstetric practices? Findings In this nonrandomized controlled trial including 98 pregnant women with opioid use disorder, there were no statistically significant differences in rates of retention in treatment between women receiving opioid use disorder treatment via telemedicine vs in person (80.4% vs 92.7%). These findings were also apparent in newborns with neonatal abstinence syndrome (telemedicine: 45.4% vs in person: 63.2%). Meaning Telemedicine may provide a scalable solution to making lifesaving treatment available to pregnant women to reduce the maternal morbidity and mortality associated with opioid use disorder and improve maternal and child health.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom